Artiva Biotherapeutics (ARTV) Equity Average (2023 - 2025)
Historic Equity Average for Artiva Biotherapeutics (ARTV) over the last 3 years, with Q3 2025 value amounting to $139.1 million.
- Artiva Biotherapeutics' Equity Average rose 271104.15% to $139.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $139.1 million, marking a year-over-year increase of 271104.15%. This contributed to the annual value of $12.3 million for FY2024, which is N/A changed from last year.
- Latest data reveals that Artiva Biotherapeutics reported Equity Average of $139.1 million as of Q3 2025, which was up 271104.15% from $158.9 million recorded in Q2 2025.
- In the past 5 years, Artiva Biotherapeutics' Equity Average ranged from a high of $193.8 million in Q4 2024 and a low of -$182.9 million during Q2 2024
- Moreover, its 3-year median value for Equity Average was $4.9 million (2024), whereas its average is $967388.9.
- As far as peak fluctuations go, Artiva Biotherapeutics' Equity Average surged by 10313.55% in 2024, and later skyrocketed by 271104.15% in 2025.
- Quarter analysis of 3 years shows Artiva Biotherapeutics' Equity Average stood at -$156.7 million in 2023, then soared by 223.66% to $193.8 million in 2024, then decreased by 28.22% to $139.1 million in 2025.
- Its Equity Average stands at $139.1 million for Q3 2025, versus $158.9 million for Q2 2025 and $177.7 million for Q1 2025.